# A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers

> **NCT02728830** · EARLY_PHASE1 · COMPLETED · sponsor: **AA Secord** · enrollment: 39 (actual)

## Conditions studied

- Gynecologic Neoplasms
- Epithelial Ovarian Cancer
- Uterine Endometrial Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02728830
- **Lead sponsor:** AA Secord
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2019-01-31
- **Final completion:** 2022-01-31
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2024-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02728830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02728830, "A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02728830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*